DEPRESSION
CYMBALTA Despite Prozac's much heralded introduction in 1987, its ability to adjust serotonin levels in the brain works for only about 30% of depressed patients. Undeterred, Prozac's maker, Eli Lilly, has filed for FDA approval of Cymbalta, an antidepressant that targets not just serotonin but norepinephrine levels as well. The FDA should decide by the end of the year. In tests, patients taking Cymbalta were up to three times as likely to find relief from depression as those taking a placebo.
CHOLESTEROL
CRESTOR Dubbed the superstatin, this newest member of the cholesterol-lowering-drug family reduces blood lipid levels in some cases...
To continue reading:
or
Log-In
